Late Response to Anti-CGRP Monoclonal Antibodies in Migraine

Review Clinical Neurology

European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention-2022 update

Simona Sacco et al.

Summary: This guideline evaluated the effectiveness and safety of monoclonal antibodies targeting the CGRP pathway for migraine prevention through systematic review and literature analysis, and provided updated treatment recommendations.

JOURNAL OF HEADACHE AND PAIN (2022)

Add to Collection

Article Clinical Neurology

Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients

Piero Barbanti et al.

Summary: This study investigates the predictors of response to antiCGRP mAbs in patients with high-frequency episodic migraine (HFEM) and chronic migraine (CM). The results show that in HFEM, unilateral pain + unilateral cranial autonomic symptoms are positively associated with >= 50% response. In CM, allodynia + unilateral pain, unilateral cranial autonomic symptoms are positively associated with >= 50% response, while obesity is negatively associated with >= 50% response. This study is important for predicting the response of migraine patients to antiCGRP mAbs.

JOURNAL OF HEADACHE AND PAIN (2022)

Add to Collection

Article Clinical Neurology